Nevro’s HFX Offers Durable Benefit In People Suffering Diabetic Pain
New 24-month data from the SENZA-PDN trial, presented at the American Diabetes Society conference in New Orleans, provides more support for HFX 10 kHz as a reliable therapy for people with painful diabetic neuropathy.
You may also be interested in...
News We're Watching: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.
Medicare’s recent expansion of coverage for spinal cord stimulation therapy to treat diabetic peripheral neuropathy could mean relief for some 11 million Americans. Executives from Redwood City, CA device maker Nevro talked to Medtech Insight about the expansion and what it means for patients who use their technology.
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.